Privia Health Group (NASDAQ:PRVA) CEO Sells $960,097.14 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CEO Parth Mehrotra sold 41,999 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $22.86, for a total transaction of $960,097.14. Following the sale, the chief executive officer directly owned 343,795 shares of the company’s stock, valued at $7,859,153.70. The trade was a 10.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Parth Mehrotra also recently made the following trade(s):

• On Tuesday, March 10th, Parth Mehrotra sold 21,097 shares of Privia Health Group stock. The stock was sold at an average price of $22.71, for a total transaction of $479,112.87.
• On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total transaction of $496,336.00.

Privia Health Group Price Performance

NASDAQ PRVA opened at $21.73 on Friday. Privia Health Group, Inc. has a 12 month low of $18.77 and a 12 month high of $26.51. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of 127.82, a price-to-earnings-growth ratio of 1.39 and a beta of 0.82. The company’s fifty day moving average price is $22.93 and its two-hundred day moving average price is $23.58.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.21. The company had revenue of $541.17 million during the quarter, compared to analyst estimates of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The firm’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same period last year, the business earned $0.21 EPS. As a group, analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Hedge Funds Weigh In On Privia Health Group

Institutional investors have recently made changes to their positions in the stock. Bayban bought a new stake in shares of Privia Health Group in the 4th quarter worth approximately $26,000. Invesco Ltd. grew its stake in Privia Health Group by 5.1% during the 4th quarter. Invesco Ltd. now owns 427,615 shares of the company’s stock worth $10,139,000 after buying an additional 20,652 shares during the last quarter. Wellington Management Group LLP increased its position in Privia Health Group by 3.8% in the fourth quarter. Wellington Management Group LLP now owns 233,446 shares of the company’s stock worth $5,535,000 after buying an additional 8,531 shares during the period. Millennium Management LLC lifted its stake in Privia Health Group by 19.0% in the fourth quarter. Millennium Management LLC now owns 702,744 shares of the company’s stock valued at $16,662,000 after buying an additional 112,428 shares during the last quarter. Finally, Gotham Asset Management LLC lifted its stake in Privia Health Group by 22.4% in the fourth quarter. Gotham Asset Management LLC now owns 36,995 shares of the company’s stock valued at $877,000 after buying an additional 6,773 shares during the last quarter. 94.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $36.00 price objective on shares of Privia Health Group in a report on Thursday, February 26th. Canaccord Genuity Group lifted their target price on Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Citigroup lowered their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Stephens reissued an “overweight” rating and set a $32.00 price target on shares of Privia Health Group in a research report on Thursday, December 4th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Privia Health Group in a research note on Monday, December 29th. Thirteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Privia Health Group presently has an average rating of “Moderate Buy” and a consensus target price of $31.00.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.